Overview

AMG 827 in Subjects With Psoriatic Arthritis

Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.
Treatments:
Antibodies, Monoclonal
Brodalumab